161 related articles for article (PubMed ID: 37330137)
1. Immune Checkpoint Inhibitor-Induced Myocarditis With Concurrent Myasthenia Gravis.
Kuniyoshi J; Huang R; Choi H; Bernas M; Techasatian W; Nishimura Y
Can J Cardiol; 2023 Nov; 39(11):1646-1648. PubMed ID: 37330137
[No Abstract] [Full Text] [Related]
2. Nivolumab and Ipilimumab-induced myositis and myocarditis mimicking a myasthenia gravis presentation.
Valenti-Azcarate R; Esparragosa Vazquez I; Toledano Illan C; Idoate Gastearena MA; Gállego Pérez-Larraya J
Neuromuscul Disord; 2020 Jan; 30(1):67-69. PubMed ID: 31839404
[TBL] [Abstract][Full Text] [Related]
3. [Immune Checkpoint Inhibitors-induced Myasthenia Gravis: From Diagnosis to Treatment].
Yao S; Li X; Nong J; Zhang Y
Zhongguo Fei Ai Za Zhi; 2020 Aug; 23(8):685-688. PubMed ID: 32752585
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitor-associated myasthenia gravis, myositis, and myocarditis overlap syndrome.
Lipe DN; Galvis-Carvajal E; Rajha E; Wechsler AH; Gaeta S
Am J Emerg Med; 2021 Aug; 46():51-55. PubMed ID: 33721590
[TBL] [Abstract][Full Text] [Related]
5. Consider Myocarditis When Patients Treated with Immune Checkpoint Inhibitors Present with Ocular Symptoms.
Rhee JY; Torun N; Neilan TG; Guidon AC
Oncologist; 2022 May; 27(5):e402-e405. PubMed ID: 35348772
[TBL] [Abstract][Full Text] [Related]
6. Immune checkpoint inhibitor-mediated myasthenia gravis with focal subclinical myocarditis progressing to symptomatic cardiac disease.
Leaver PJ; Jang HS; Vernon ST; Fernando SL
BMJ Case Rep; 2020 May; 13(5):. PubMed ID: 32404371
[TBL] [Abstract][Full Text] [Related]
7. Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the US Food and Drug Administration Adverse Event Reporting System.
Niimura T; Zamami Y; Miyata K; Mikami T; Asada M; Fukushima K; Yoshino M; Mitsuboshi S; Okada N; Hamano H; Sakurada T; Matsuoka-Ando R; Aizawa F; Yagi K; Goda M; Chuma M; Koyama T; Izawa-Ishizawa Y; Yanagawa H; Fujino H; Yamanishi Y; Ishizawa K
J Clin Pharmacol; 2023 Apr; 63(4):473-479. PubMed ID: 36453166
[TBL] [Abstract][Full Text] [Related]
8. PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis.
So H; Ikeguchi R; Kobayashi M; Suzuki M; Shimizu Y; Kitagawa K
J Neurol Sci; 2019 Apr; 399():97-100. PubMed ID: 30798111
[No Abstract] [Full Text] [Related]
9. Durvalumab-induced myocarditis, myositis, and myasthenia gravis: a case report.
Cham J; Ng D; Nicholson L
J Med Case Rep; 2021 May; 15(1):278. PubMed ID: 34053457
[TBL] [Abstract][Full Text] [Related]
10. Myasthenia gravis, myositis and myocarditis: a fatal triad of immune-related adverse effect of immune checkpoint inhibitor treatment.
Soman B; Dias MC; Rizvi SAJ; Kardos A
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36593626
[TBL] [Abstract][Full Text] [Related]
11. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
Fazal M; Prentice DA; Kho LK; Fysh E
Intern Med J; 2020 Aug; 50(8):1003-1006. PubMed ID: 33306231
[TBL] [Abstract][Full Text] [Related]
13. Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review.
Liang S; Yang J; Lin Y; Li T; Zhao W; Zhao J; Dong C
Front Immunol; 2021; 12():682262. PubMed ID: 34305915
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint inhibitor-related myasthenia gravis, myositis and myocarditis: a triad but not at the same time?
Cooksley T; Weaver J; McNamara M; Lorigan P
QJM; 2024 Jun; 117(5):373-374. PubMed ID: 38229249
[No Abstract] [Full Text] [Related]
15. Immune checkpoint inhibitor-induced myocarditis, myositis, myasthenia gravis and transaminitis: a case series and review.
Wai Siu DH; O'Neill RS; Harris CA; Wang J; Ardolino L; Downton T; Tong M; Hong JH; Chin V; Clingan PR; Aghmesheh M; Soudy H
Immunotherapy; 2022 May; 14(7):511-520. PubMed ID: 35321560
[TBL] [Abstract][Full Text] [Related]
16. Presence of antibodies to striated muscle and acetylcholine receptor in association with occurrence of myasthenia gravis with myositis and myocarditis in a patient with melanoma treated with an anti-programmed death 1 antibody.
Shirai T; Kiniwa Y; Sato R; Sano T; Nakamura K; Mikoshiba Y; Ohashi N; Sekijima Y; Okuyama R
Eur J Cancer; 2019 Jan; 106():193-195. PubMed ID: 30528803
[No Abstract] [Full Text] [Related]
17. Spontaneous development of myasthenia gravis and myositis following treatment with pembrolizumab: a case report.
Kiaei B; Chaudhry M; Banerjee S; Brewer J; Chen Y; Khasiyev F; Guzman MA; Hayat G
BMC Neurol; 2024 Jun; 24(1):184. PubMed ID: 38824498
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review.
Gao L; Li X; Guo Z; Tang L; Peng J; Liu B
Medicine (Baltimore); 2022 Dec; 101(49):e32240. PubMed ID: 36626474
[TBL] [Abstract][Full Text] [Related]
19. Asymptomatic Immune Checkpoint Inhibitor-associated Myocarditis.
Tanabe J; Watanabe N; Endo A; Nagami T; Inagaki S; Tanabe K
Intern Med; 2021 Feb; 60(4):569-573. PubMed ID: 33028770
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians.
Raschi E; Rossi S; De Giglio A; Fusaroli M; Burgazzi F; Rinaldi R; Potena L
Drug Saf; 2023 Sep; 46(9):819-833. PubMed ID: 37341925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
